110 HR 962 IH: Preservation of Antibiotics for Medical Treatment Act of 2007
U.S. House of Representatives
2007-02-08
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I
110th CONGRESS 1st Session
H. R. 962
IN THE HOUSE OF REPRESENTATIVES

February 8, 2007
Ms. Slaughter introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL
To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.

1.Short title; table of contents
(a)Short titleThis Act may be cited as the Preservation of Antibiotics for Medical Treatment Act of 2007.
(b)Table of contentsThe table of contents of this Act is as follows:

Sec. 1. Short title; table of contents.
Sec. 2. Findings.
Sec. 3. Purpose.
Title I—Safety of critical antimicrobial animal drugs
Sec. 101. Proof of safety of critical antimicrobial animal drugs.
Title II—Use of critical antimicrobial animal drugs in agriculture
Sec. 201. Collection of data on critical antimicrobial animal drugs.
2.FindingsThe Congress finds that—
(1)
(A)in January 2001, a Federal interagency task force released an action plan to address the continuing decline in effectiveness of antibiotics against common bacterial infections, referred to as antibiotic resistance;
(B)the task force determined that antibiotic resistance is a growing menace to all people and poses a serious threat to public health; and
(C)the task force cautioned that if current trends continue, treatments for common infections will become increasingly limited and expensive, and, in some cases, nonexistent;
(2)antibiotic resistance, resulting in a reduced number of effective antibiotics, may significantly impair the ability of the United States to respond to terrorist attacks involving bacterial infections or a large influx of hospitalized patients;
(3)
(A)any overuse or misuse of antibiotics contributes to the spread of antibiotic resistance, whether in human medicine or in agriculture; and
(B)recognizing the public health threat caused by antibiotic resistance, Congress took several steps to curb antibiotic overuse in human medicine through amendments to the Public Health Service Act (42 U.S.C. 201 et seq.) made by section 102 of the Public Health Threats and Emergencies Act (Public Law 106–505, title I; 114 Stat. 2315), but has not yet addressed antibiotic overuse in agriculture;
(4)in a March 2003 report, the National Academy of Sciences stated that—
(A)a decrease in antimicrobial use in human medicine alone will have little effect on the current situation; and
(B)substantial efforts must be made to decrease inappropriate overuse in animals and agriculture;
(5)
(A)an estimated 70 percent of the antibiotics and other antimicrobial drugs used in the United States are fed to farm animals for nontherapeutic purposes, including—
(i)growth promotion; and
(ii)compensation for crowded, unsanitary, and stressful farming and transportation conditions; and
(B)unlike human use of antibiotics, these nontherapeutic uses in animals typically do not require a prescription;
(6)
(A)many scientific studies confirm that the nontherapeutic use of antibiotics in agricultural animals contributes to the development of antibiotic-resistant bacterial infections in people;
(B)the periodical entitled Clinical Infectious Diseases published a report in June 2002, based on a 2-year review by experts in human and veterinary medicine, public health, microbiology, biostatistics, and risk analysis, of more than 500 scientific studies on the human health impacts of antimicrobial use in agriculture; and
(C)the report recommended that antimicrobial agents should no longer be used in agriculture in the absence of disease, but should be limited to therapy for diseased individual animals and prophylaxis when disease is documented in a herd or flock;
(7)the United States Geological Survey reported in March 2002 that—
(A)antibiotics were present in 48 percent of the streams tested nationwide; and
(B)almost half of the tested streams were downstream from agricultural operations;
(8)an April 1999 study by the General Accounting Office concluded that resistant strains of 3 microorganisms that cause food-borne illness or disease in humans—Salmonella, Campylobacter, and E. coli—are linked to the use of antibiotics in animals;
(9)
(A)in January 2003, Consumer Reports published test results on poultry products bought in grocery stores nationwide showing disturbingly high levels of Campylobacter and Salmonella bacteria that were resistant to antibiotics used to treat food-borne illnesses; and
(B)further studies showed similar results in other meat products;
(10)in October 2001, the New England Journal of Medicine published an editorial urging a ban on nontherapeutic use of medically important antibiotics in animals;
(11)
(A)in 1999, the European Union banned the practice of feeding medically important antibiotics to animals other than for disease treatment or control, and prior to that, individual European countries had banned the use of specific antibiotics in animal feed; and
(B)those countries have experienced no significant impact on animal health or productivity, food safety, or meat prices, and more importantly, levels of resistant bacteria have declined sharply;
(12)in 1998, the National Academy of Sciences noted that antibiotic-resistant bacteria generate a minimum of $4,000,000,000 to $5,000,000,000 in costs to United States society and individuals yearly;
(13)a year later, the National Academy of Sciences estimated that eliminating the use of all antibiotics as feed additives would cost each American consumer less than $5 to $10 per year;
(14)the American Medical Association, the American Public Health Association, the National Association of County and City Health Officials, and the National Campaign for Sustainable Agriculture, are among the more than 300 organizations representing health, consumer, agricultural, environmental, humane, and other interests that support enactment of legislation to phase out nontherapeutic use in farm animals of medically important antibiotics;
(15)the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.)—
(A)requires that all drugs be shown to be safe before the drugs are approved; and
(B)places the burden on manufacturers to account for health consequences and prove safety;
(16)
(A)the Food and Drug Administration recently modified the drug approval process for antibiotics to recognize the development of resistant bacteria as an important aspect of safety;
(B)however, most antibiotics currently used in animal production systems for nontherapeutic purposes were approved before the Food and Drug Administration began giving in-depth consideration to resistance during the drug-approval process; and
(C)the Food and Drug Administration has not established a schedule for reviewing those existing approvals; and
(17)certain non-routine uses of antibiotics in animal agriculture are legitimate to prevent animal disease; and
(18)
(A)an April 2004 study by the General Accounting Office concluded that Federal agencies do not collect the critical data on antibiotic use in animals that they need to support research on human health risks; and
(B)the report recommends that the Department of Agrigulture and the Department of Health and Human Services develop and implement a plan to collect data on antibiotic use in animals.
3.PurposeThe purpose of this Act is to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases by phasing out use of certain antibiotics for nontherapeutic purposes in food-producing animals.
ISafety of critical antimicrobial animal drugs
101.Proof of safety of critical antimicrobial animal drugs
(a)DefinitionsSection 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321) is amended by adding at the end the following:

(rr)Critical antimicrobial animal drugThe term critical antimicrobial animal drug means a drug that—
(1)is intended for use in food-producing animals; and
(2)is composed wholly or partly of—
(A)any kind of penicillin, tetracycline, macrolide, lincosamide, streptogramin, aminoglycoside, or sulfonamide; or
(B)any other drug or derivative of a drug that is used in humans or intended for use in humans to treat or prevent disease or infection caused by microorganisms.
(ss)Nontherapeutic useThe term nontherapeutic use, with respect to a critical antimicrobial animal drug, means any use of the drug as a feed or water additive for an animal in the absence of any clinical sign of disease in the animal for growth promotion, feed efficiency, weight gain, routine disease prevention, or other routine purpose..
(b)Applications pending or submitted after enactmentSection 512(d)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(d)(1)) is amended—
(1)in the first sentence—
(A)in subparagraph (H), by striking or at the end;
(B)by redesignating subparagraph (I) as subparagraph (J); and
(C)by inserting after subparagraph (H) the following:

(I)with respect to a critical antimicrobial animal drug or a drug of the same chemical class as a critical antimicrobial animal drug, the applicant has failed to demonstrate that there is a reasonable certainty of no harm to human health due to the development of antimicrobial resistance that is attributable, in whole or in part, to the nontherapeutic use of the drug; or; and
(2)in the second sentence, by striking (A) through (I) and inserting (A) through (J).
(c)Phased elimination of nontherapeutic use in animals of critical antimicrobial animal drugs important for human healthSection 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b) is amended by adding at the end the following:

(q)Phased elimination of nontherapeutic use in animals of critical antimicrobial animal drugs important for human health
(1)ApplicabilityThis subsection applies to the nontherapeutic use in a food-producing animal of a drug—
(A)
(i)that is a critical antimicrobial animal drug; or
(ii)that is of the same chemical class as a critical antimicrobial animal drug; and
(B)
(i)for which there is in effect an approval of an application or an exemption under subsection (b), (i), or (j) of section 505; or
(ii)that is otherwise marketed for use.
(2)WithdrawalThe Secretary shall withdraw the approval of a nontherapeutic use in food-producing animals described in paragraph (1) on the date that is 2 years after the date of enactment of this subsection unless—
(A)before the date that is 2 years after the date of the enactment of this subsection, the Secretary makes a final written determination that the holder of the approved application has demonstrated that there is a reasonable certainty of no harm to human health due to the development of antimicrobial resistance that is attributable in whole or in part to the nontherapeutic use of the drug; or
(B)before the date specified in subparagraph (A), the Secretary makes a final written determination under this subsection, with respect to a risk analysis of the drug conducted by the Secretary and other relevant information, that there is a reasonable certainty of no harm to human health due to the development of antimicrobial resistance that is attributable in whole or in part to the nontherapeutic use of the drug.
(3)ExemptionsExcept as provided in paragraph (5), if the Secretary grants an exemption under section 505(i) for a drug that is a critical antimicrobial animal drug, the Secretary shall rescind each approval of a nontherapeutic use in a food-producing animal of the critical antimicrobial animal drug, or of a drug in the same chemical class as the critical antimicrobial animal drug, as of the date that is 2 years after the date on which the Secretary grants the exemption.
(4)ApprovalsExcept as provided in paragraph (5), if an application for a drug that is a critical antimicrobial animal drug is submitted to the Secretary under section 505(b), the Secretary shall rescind each approval of a nontherapeutic use in a food-producing animal of the critical antimicrobial animal drug, or of a drug in the same chemical class as the critical antimicrobial animal drug, as of the date that is 2 years after the date on which the application is submitted to the Secretary.
(5)ExceptionParagraph (3) or (4), as the case may be, shall not apply if—
(A)before the date on which approval would be rescinded under that paragraph, the Secretary makes a final written determination that the holder of the application for the approved nontherapeutic use has demonstrated that there is a reasonable certainty of no harm to human health due to the development of antimicrobial resistance that is attributable in whole or in part to the nontherapeutic use in the food-producing animal of the critical antimicrobial animal drug; or
(B)before the date specified in subparagraph (A), the Secretary makes a final written determination under this subsection, with respect to a risk analysis of the critical antimicrobial animal drug conducted by the Secretary and any other relevant information, that there is a reasonable certainty of no harm to human health due to the development of antimicrobial resistance that is attributable in whole or in part to the nontherapeutic use of the drug..
IIUse of critical antimicrobial animal drugs in agriculture
201.Collection of data on critical antimicrobial animal drugs
(a)In generalChapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 512 (21 U.S.C. 360b) the following:

512A.Collection of data on critical antimicrobial animal drugs
(a)In generalNot later than July 1 of each year, a manufacturer of a critical antimicrobial animal drug or an animal feed for food-producing animals bearing or containing a critical antimicrobial animal drug shall submit to the Secretary a report, in such form as the Secretary shall require, containing information on the sales during the previous calendar year of the critical antimicrobial animal drug or the animal feed.
(b)Information To be includedA report under subsection (a) shall—
(1)state separately the quantity of the critical antimicrobial animal drug, including such quantity in animal feed bearing or containing the critical antimicrobial drug, sold for each kind of food-producing animal;
(2)describe the claimed purpose of use for the drug for each kind of food-producing animal as being for growth promotion, weight gain, feed efficiency, disease prevention, disease control, disease treatment, or another purpose; and
(3)describe the dosage form of the drug.
(c)Publication
(1)In generalThe Secretary shall make the information submitted under subsection (a) available to the public not less than annually.
(2)Protection of confidentialityThe Secretary may aggregate information, if necessary, so as to avoid disclosure under paragraph (1) of confidential business information..
(b)ViolationSubsection (e) of section 301 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 331(e)) is amended by striking 515(f) and inserting 512A, 515(f).
(c)Effective dateThe amendments made by this section shall take effect on January 1, 2008.


115 HR 897 IH: To authorize the Secretary of Veterans Affairs to make grants to State and local entities to carry out peer-to-peer mental health programs.
U.S. House of Representatives
2017-02-06
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 897IN THE HOUSE OF REPRESENTATIVESFebruary 6, 2017Mr. Zeldin (for himself, Mr. King of New York, Mr. Suozzi, and Miss Rice of New York) introduced the following bill; which was referred to the Committee on Veterans' AffairsA BILLTo authorize the Secretary of Veterans Affairs to make grants to State and local entities to carry
			 out peer-to-peer mental health programs.

		1.P.F.C. Joseph P. Dwyer Peer Support Program
 (a)In generalThe Secretary of Veterans Affairs shall establish a grant program to be known as the P.F.C. Joseph P. Dwyer Peer Support Program under which the Secretary shall make grants to eligible entities for the purpose of establishing peer-to-peer mental health programs for veterans.
 (b)Eligible entity definedIn this section, the term eligible entity means any of the following entities that submit to the Secretary an application containing such information and assurances as the Secretary may require:
 (1)A nonprofit organization having historically served veterans mental health needs. (2)A congressionally chartered veteran service organization.
 (3)A State, local, or tribal veteran service agency, director, or commissioner. (c)Amount of grantThe recipient of a grant under this section shall receive a grant in an amount that does not exceed $250,000.
 (d)Use of fundsThe recipient of a grant under this section shall use the grant funds to— (1)carry out a program that meets the standards developed under subsection (e);
 (2)hire veterans to serve as peer specialists to host group and individual meetings with veterans seeking nonclinical support;
 (3)provide mental health support to veterans 24 hours each day, seven days each week; and (4)hire staff to support the program.
				(e)Program standards
 (1)Advisory commissionThe Secretary shall establish an advisory committee for the purpose of creating appropriate standards applicable to programs established using grants under this section.
 (2)StandardsThe standards developed under paragraph (1) shall include initial and continued training for veteran peer volunteers, administrative staffing needs, and best practices for addressing the needs of each veteran served.
 (f)Nonretention of recordsThe Secretary may not require the recipient of a grant under this section to maintain records on veterans seeking support or to report any personally identifying information directly or indirectly to the Secretary about such veterans.
 (g)Authorization of appropriationsThere is authorized to be appropriated $25,000,000 to carry out this section during the 3-year period beginning on the date of the enactment of this Act.


116 S476 IS: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
U.S. Senate
2019-02-13
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II
116th CONGRESS1st Session
S. 476
IN THE SENATE OF THE UNITED STATES

February 13, 2019
Mr. Wyden (for himself, Mr. Brown, Mr. Carper, and Mr. Tester) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL
To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.

1.Short titleThis Act may be cited as the Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019.  2.Public disclosure of drug discounts (a)In generalSection 1150A of the Social Security Act (42 U.S.C. 1320b–23) is amended—
(1)in subsection (c), in the matter preceding paragraph (1), by striking this section and inserting subsection (b)(1); and  (2)by adding at the end the following new subsection:

(e)Public availability of certain informationIn order to allow patients and employers to compare PBMs’ ability to negotiate rebates, discounts, and price concessions and the amount of such rebates, discounts, and price concessions that are passed through to plan sponsors, beginning January 1, 2020, the Secretary shall make available on the Internet website of the Department of Health and Human Services the information provided to the Secretary under paragraphs (2) and (3) of subsection (b) with respect to each PBM. The Secretary shall ensure that such information is displayed in a manner that prevents the disclosure of information on rebates, discounts, and price concessions with respect to an individual drug or an individual plan..  (b)Effective dateThe amendments made by subsection (a) shall take effect on January 1, 2020.
3.Minimum drug discounts required To be passed through to the plan sponsor
(a)In generalSection 1150A of the Social Security Act (42 U.S.C. 1320b–23), as amended by section 2(a)(2), is amended— (1)in the heading, by inserting ; minimum drug discounts required to be passed through to the plan sponsor before the period at the end; and
(2)by adding at the end the following new subsection:  (f)Minimum drug discounts required To be passed through to the plan sponsor (1)RequirementBeginning January 1, 2022, a PBM that manages prescription drug coverage under a contract with a PDP sponsor or MA organization described in subsection (b)(1) or a qualified health benefits plan described in subsection (b)(2), shall, with respect to the plan sponsor of a health benefits plan, pass through to the plan sponsor a minimum percent (as established by the Secretary) of the aggregate amount of the rebates, discounts, or price concessions that the PBM negotiates that are attributable to patient utilization under the plan.
(2)EstablishmentThe Secretary shall establish the minimum percent described in paragraph (1) in such a manner as will ensure that patients receive the maximum benefit of rebates, discounts, or price concessions while taking into account the costs of negotiating such rebates, discounts, and price concessions.  (3)EnforcementA PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan under part D of title XVIII may not contract with a PBM that is not in compliance with the requirement under paragraph (1)..
(b)Effective dateThe amendments made by subsection (a) shall take effect on January 1, 2022.  4.Part D negotiated prices required to take into account all price concessions at the point-of-sale (a)In generalSection 1860D–2(d)(1)(B) of the Social Security Act (42 U.S.C. 1395w–102(d)(1)(B)) is amended—
(1)by striking prices.—For purposes and inserting “prices.—  (i)In generalFor purposes; and
(2)by adding at the end the following new clause:  (ii)Negotiated prices at point-of-sale (I)In generalNegotiated prices for covered part D drugs described in clause (i), including all price negotiated concessions, shall be provided at the point-of-sale of the covered part D drug. If the negotiated price, including all negotiated price concessions, is not possible to calculate at the point-of-sale, an approximate negotiated price (as established by the Secretary) shall be used under the prescription drug plan or MA–PD plan.
(II)Approximate negotiated priceIn determining an approximate negotiated price for a covered part D drug under subclause (I), the Secretary shall ensure that— (aa)such price reflects the estimated negotiated price that is based on the previous year’s negotiated price concessions negotiated under the plan for all or similar covered part D drugs or is based on such other factors as the Secretary may determine appropriate; and
(bb)the use of such price does not prevent the use of value-based contracts between drug manufacturers, PDP sponsors, MA organizations, and pharmacies..  (b)Effective dateThe amendments made by subsection (a) shall apply to plan years beginning on or after January 1, 2021.


IV
111th CONGRESS
1st Session
H. RES. 456
In the House of Representatives, U. S.,

May 20, 2009

RESOLUTION
Providing for the consideration of the Senate amendment to the bill (H.R. 627) to amend the Truth in Lending Act to establish fair and transparent practices relating to the extension of credit under an open end consumer credit plan, and for other purposes.

That upon adoption of this resolution it shall be in order to take from the Speaker's table the bill (H.R. 627) to amend the Truth in Lending Act to establish fair and transparent practices relating to the extension of credit under an open end consumer credit plan, and for other purposes, with the Senate amendment thereto, and to consider in the House, without intervention of any point of order except those arising under clause 10 of rule XXI, a motion offered by the chair of the Committee on Financial Services or his designee that the House concur in the Senate amendment. The Senate amendment shall be considered as read. The motion shall be debatable for one hour equally divided and controlled by the chair and ranking minority member of the Committee on Financial Services. The previous question shall be considered as ordered on the motion to its adoption without intervening motion. The question of adoption of the motion shall be divided for a separate vote on concurring in section 512 of the Senate amendment.
2.If either portion of the divided question fails of adoption, then the House shall be considered to have made no disposition of the Senate amendment.
3.House Resolution 450 is laid on the table.

Lorraine C. Miller,Clerk.


116 HR 6908 IH: Afghanistan Security and Reconstruction Transparency Act
U.S. House of Representatives
2020-05-15
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I116th CONGRESS2d SessionH. R. 6908IN THE HOUSE OF REPRESENTATIVESMay 15, 2020Mr. Lynch (for himself, Mr. Connolly, Mr. Cooper, Ms. Wasserman Schultz, Mr. Rouda, Mr. Welch, Mrs. Lawrence, Ms. Speier, and Ms. Kelly of Illinois) introduced the following bill; which was referred to the Committee on Foreign Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo provide for public availability of data pertaining to measures of performance of the Afghan National Defense and Security Forces, and for other purposes.1.Short titleThis Act may be cited as the Afghanistan Security and Reconstruction Transparency Act. 2.Public availability of data pertaining to measures of performance of the Afghan National Defense and Security Forces(a)In generalNot later than 90 days after the date of the enactment of this Act, the Secretary of Defense shall make publicly available all data pertaining to measures of performance of the Afghan National Defense and Security Forces (hereafter in this section referred to as ANDSF).(b)Data To be includedThe data required to be made publicly available by subsection (a) shall include the following:(1)The total quarterly ANDSF attrition rate and quarterly attrition rates for ANDSF components, including the Afghan National Army, the Afghan National Police, the Afghan Air Force, and the Afghan Local Police.(2)The total number of ANDSF personnel dropped from the rolls for the quarter and the number of personnel dropped from the rolls by ANDSF component for the quarter.(3)The total number of ANDSF personnel trained to date, the number of new ANDSF personnel that entered training for the quarter, the number of new ANDSF personnel that completed training for the quarter, the total number of personnel trained by ANDSF component to date, the number of new personnel by ANDSF component that entered training for the quarter, and the number of new personnel by ANDSF component that completed training for the quarter.(4)The total number and percentage of unfilled ANDSF positions and the number and percentage of unfilled positions by ANDSF component.(5)The percentage of ANDSF components assessed at full authorized and assigned strength.(6)Detailed Afghan Ministry of Defense, Ministry of Interior, and ANDSF performance assessments.(7)Information about the operational readiness of Afghan National Army and Afghan National Police equipment.(8)Afghanistan Special Mission Wing information, including the number and type of airframes, the number of pilots and aircrew, and the operational readiness (and associated benchmarks) of airframes. (9)Enemy-initiated attacks and effective enemy-initiated attacks on the ANDSF.3.District-level stability assessments of Afghan government and insurgent control and influence(a)In generalThe Secretary of Defense shall resume the production of district-level stability assessments of Afghan government and insurgent control and influence that were discontinued in 2018, to include district, population, and territorial control data. (b)Public availabilityThe Secretary of Defense shall make publicly available the assessments and all data pertaining to the assessments produced under subsection (a).


I
One Hundred Twelfth Congress of the United States of America At the First SessionBegun and held at the City of Washington on Wednesday, the fifth day of January, two thousand and eleven
H. R. 1975

AN ACT
To designate the facility of the United States Postal Service located at 281 East Colorado Boulevard in Pasadena, California, as the First Lieutenant Oliver Goodall Post Office Building.

1.First Lieutenant Oliver Goodall Post Office Building
(a)DesignationThe facility of the United States Postal Service located at 281 East Colorado Boulevard in Pasadena, California, shall be known and designated as the First Lieutenant Oliver Goodall Post Office Building.
(b)ReferencesAny reference in a law, map, regulation, document, paper, or other record of the United States to the facility referred to in subsection (a) shall be deemed to be a reference to the First Lieutenant Oliver Goodall Post Office Building.
 Speaker of the House of Representatives.Vice President of the United States and President of the Senate.


110 HRES 478 EH: Electing a member to the Joint Committee on Printing.
U.S. House of Representatives
2007-06-12
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV
110th CONGRESS
1st Session
H. RES. 478
In the House of Representatives, U. S.,

June 12, 2007

RESOLUTION
Electing a member to the Joint Committee on Printing.

That the following named Member be, and is hereby, elected to the following standing committee of the House of Representatives to rank after Mr. Capuano:

 Joint Committee on Printing:Mrs. Davis of California.

Lorraine C. Miller,Clerk.


		I
		112th CONGRESS
		2d Session
		H. R. 6362
		IN THE HOUSE OF REPRESENTATIVES

			September 10, 2012
			Mr. Thompson of
			 California (for himself, Mrs.
			 Capps, Mr. DeFazio,
			 Ms. Eshoo,
			 Mr. Farr, Ms. Herrera Beutler, Mr. Larsen of Washington,
			 Mr. Schrader,
			 Ms. Speier,
			 Ms. Woolsey, and
			 Mr. Young of Alaska) introduced the
			 following bill; which was referred to the Committee on Natural
			 Resources

		A BILL
		To direct the Secretary of Commerce to
		  issue a fishing capacity reduction loan to refinance the existing loan funding
		  the Pacific Coast Groundfish Fishery Fishing Capacity Reduction
		  Program.

		1.Short titleThis Act may be cited as the
			 Revitalizing the Economy of Fisheries
			 in the Pacific Act of 2012 or the REFI
			 Pacific Act of 2012.
		2.Findings;
			 purpose
			(a)FindingsCongress
			 finds as follows:
				(1)In 2000, the
			 Secretary of Commerce declared the Pacific Coast Groundfish Fishery a Federal
			 fisheries disaster due to low stock abundance of groundfish and an
			 overcapitalized fleet.
				(2)In 2003, section 212 of the Department of
			 Commerce and Related Agencies Appropriations Act, 2003 (title II of division B
			 of Public Law 108–7; 117 Stat. 80) was enacted to require establishment of a
			 Pacific Coast groundfish fishery buyback program to remove excess fishing
			 capacity from the groundfish, crab, and shrimp fisheries.
				(3)In 2003, a $35,700,000 buyback loan was
			 authorized by Congress, creating the Pacific Coast Groundfish Fishing capacity
			 reduction program through the National Marine Fisheries Service Fisheries
			 Finance Program with a term of 30 years. The interest rate of the buyback loan
			 was fixed at 6.97 percent and is paid back based on an ex-vessel fee landing
			 rate of 5 percent for the loan.
				(4)The buyback program resulted in the removal
			 of limited entry trawl Federal fishing permits from the fishery, representing
			 approximately 46 percent of total landings at the time.
				(5)Because of an absence of a repayment
			 mechanism, $4,243,730 in interest was accrued before fee collection procedures
			 were established in 2005, over 18 months after the fishing capacity reduction
			 program was initiated.
				(6)In 2011, the
			 Pacific Coast groundfish fishery transitioned to a catch share program.
				(7)By 2015, Pacific
			 Coast groundfish fishermen’s expenses are expected to include fees of
			 approximately $450 per day for observers, a 3-percent cost recovery fee as
			 authorized by the Magnuson-Stevens Fishery Conservation and Management Act for
			 catch share programs, and a 5-percent ex-vessel landings rate for the loan
			 repayment, which could reach 18 percent of their total gross revenue.
				(8)In the period covering 2006 through 2011,
			 the annual average Pacific Coast Groundfish Fishery ex-vessel revenue was
			 $85,945,847, which included revenue of at-sea catcher processors, at-sea
			 mothership catcher vessels, trawls, open access, and tribal fishing and all
			 other groundfish revenue. Of that revenue, an average of $45,000,000 was
			 generated by the limited entry trawl fishery.
				(9)Currently,
			 National Oceanic and Atmospheric Administration Fisheries administers
			 industry-funded capacity reduction programs in the Bering Sea-Aleutian Islands
			 crab, Bering Sea-Aleutian Islands non-pollock groundfish, and American
			 Fisheries Act pollock fisheries, along with the Pacific Coast groundfish
			 fishery. Each program has a 30-year, long-term loan repayment period based on
			 fees for future landings in the fisheries.
				(10)A fifth reduction
			 buyback program was implemented in 2012 for the Alaska Purse Seine Salmon
			 Fishery, which has a 40-year, long-term repayment period based on fees for
			 future landings in the fishery with an ex-vessel landing rate of 3
			 percent.
				(11)In the past when
			 fishery disasters have been declared, some fisheries have been issued Federal
			 disaster assistance grants to provide short-term economic assistance to
			 fishermen leaving the industry, increased profitability for remaining
			 fishermen, and conservation of fish stocks.
				(12)In 1996 and 1997,
			 a $23,000,000 Federal disaster assistance grant was issued for the New England
			 Groundfish Fishery, which was used to remove 68 multi-species permits and scrap
			 58 vessels associated with those permits. No loan repayments were required for
			 this grant.
				(b)PurposeThe purpose of the Act is to refinance the
			 Pacific Coast Groundfish Fishery Fishing Capacity Reduction Program to protect
			 and conserve the Pacific Coast groundfish fishery, fishermen’s economic
			 livelihood, and jobs of associated industries.
			3.Refinancing of West
			 Coast Groundfish Fishery fishing capacity reduction loan
			(a)In
			 generalThe Secretary of
			 Commerce shall, upon receipt of such assurances as the Secretary considers
			 appropriate to protect the interests of the United States, issue a loan to
			 refinance the existing debt obligation funding the fishing capacity reduction
			 program for the Pacific Coast Groundfish Fishery implemented under section 212
			 of the Department of Commerce and Related Agencies Appropriations Act, 2003
			 (title II of division B of Public Law 108–7; 117 Stat. 80).
			(b)Applicable
			 lawExcept as otherwise
			 provided in this section, the Secretary shall issue such loan in accordance
			 with subsections (b) through (e) of section 312 of the Magnuson-Stevens Fishery
			 Conservation and Management Act (16 U.S.C. 1861a) and sections 53702 and 53735
			 of title 46, United States Code.
			(c)Loan
			 termNotwithstanding section
			 53735(c)(4) of title 46, United States Code, a loan under this section must
			 have a maturity that expires at the end of the 45-year period beginning on the
			 date of issuance of such loan.
			(d)Limitation on
			 fee amountNotwithstanding
			 section 312(d)(2)(B) of the Magnuson-Stevens Fishery Conservation and
			 Management Act (16 U.S.C. 1861(d)(2)(B)), the fee established by the Secretary
			 with respect to a loan under this section shall not exceed 3 percent of the
			 ex-vessel value of all fish harvested from each fishery for which the loan is
			 issued.
			(e)FundingTo
			 implement this section there is authorized to be appropriated to the Secretary
			 an amount equal to 1 percent of the amount of the loan authorized under this
			 section.


94 HJ 58 IH: Ulysses S. Grant Bicentennial Recognition Act
U.S. House of Representatives
2021-09-14
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IA117th CONGRESS1st SessionH. J. RES. 58IN THE HOUSE OF REPRESENTATIVESSeptember 14, 2021Mrs. Wagner (for herself, Mr. Espaillat, Ms. Stefanik, Mrs. Bustos, and Mr. Guest) submitted the following joint resolution; which was referred to the Committee on Armed ServicesJOINT RESOLUTIONTo provide for the appointment of Ulysses S. Grant to the grade of General of the Armies of the United States.1.Short titleThis joint resolution may be cited as the Ulysses S. Grant Bicentennial Recognition Act.2.Findings and purpose(a)FindingsCongress finds the following:(1)On March 3, 1799, Congress created the grade of General of the Armies of the United States as the commander of the Army of the United States (5th Congress, Session III, Chap. 48, Section 9).(2)On March 16, 1802, Congress effectively dissolved the grade of General of the Armies of the United States when it passed the Military Peace Establishment Act without reference to the grade (7th Congress, Session I, Chap. 9, Sec. 3).(3)On July 1, 1843, Ulysses S. Grant graduated from the United States Military Academy at West Point, and, on July 31, 1854, Grant resigned from the Army at the grade of Captain.(4)Following President Abraham Lincoln’s April 15, 1861, proclamation calling for 75,000 volunteers to suppress Confederate forces, Ulysses S. Grant rejoined the Army and helped recruit and train volunteer soldiers for the Union.(5)Over the course of the American Civil War, Ulysses S. Grant commanded a cumulative total of over 620,000 Union soldiers and achieved major victories including Fort Henry (February 1862), Fort Donelson (February 1862), Shiloh (April 1862), the Vicksburg Campaign (November 1862—July 1863), Chattanooga (November 1863), the Wilderness Campaign (May 1864—June 1864), the Petersburg Campaign (June 1864—April 1865), and the Appomattox Campaign (April 1865).(6)On February 29, 1864, Congress reestablished the grade of Lieutenant-General of the United States Army and authorized the President to appoint, by and with the advice and consent of the Senate, an officer who was most distinguished for courage, skill, and ability (38th Congress, Session I, Chap. 14, Sec. 1); that same day, President Abraham Lincoln nominated Ulysses S. Grant to be Lieutenant-General.(7)On March 10, 1864, President Abraham Lincoln formally appointed Ulysses S. Grant to the grade of Lieutenant-General of the Army, a position previously held by only George Washington and Winfield Scott, although Scott’s promotion was a brevet appointment.(8)On July 25, 1866, Congress established the grade of General of the Army of the United States (39th Congress, Session I, Chap. 232), and Ulysses S. Grant was appointed, by and with the advice and consent of the Senate, to General of the Army of the United States for his role in commanding the Union armies during the Civil War.(9)On March 4, 1869, Ulysses S. Grant was sworn in as the 18th President of the United States.(10)Throughout his two terms as President, Ulysses S. Grant secured the ratification of the 15th amendment to the Constitution, the creation of the Department of Justice, and the passage and implementation of the Civil Rights Act of 1875. (11)On October 11, 1976, Congress enacted Public Law 94–479, which re-established the grade of General of the Armies of the United States to posthumously request the appointment of George Washington to General of the Armies of the United States and made clear that this grade has precedence over all other grades of the Army, past or present.(b)PurposeThe purpose of this joint resolution is to—(1)honor Ulysses S. Grant for his efforts and leadership in defending the union of the United States of America;(2)recognize that the military victories achieved under the command of Ulysses S. Grant were integral to the preservation of the United States of America; and(3)affirm that Ulysses S. Grant is among the most influential military commanders in the history of the United States of America.3.AppointmentThe President is authorized and requested to appoint Ulysses S. Grant posthumously to the grade of General of the Armies of the United States, such appointment to take effect on April 27, 2022.


109 HR 645 IH: To suspend temporarily the duty on TMPDE.
U.S. House of Representatives
2005-02-08
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I
109th CONGRESS
1st Session
H. R. 645
IN THE HOUSE OF REPRESENTATIVES

February 8, 2005
Ms. Kaptur introduced the following bill; which was referred to the Committee on Ways and Means

A BILL
To suspend temporarily the duty on TMPDE.

1.TMPDE
(a)In generalSubchapter II of chapter 99 of the Harmonized Tariff Schedule of the United States is amended by inserting in numerical sequence the following new heading:

“9902.07.10Trimethylolpropane, dlallyl ether (CAS No. 682–09–7) (provided for in subheading 2909.49.60)FreeFreeNo changeOn or before 12/31/2008.
(b)Effective dateThe amendment made by subsection (a) applies with respect to goods entered, or withdrawn from warehouse for consumption, on or after the 15th day after the date of the enactment of this Act.


		IV
		112th CONGRESS
		1st Session
		H. RES. 284
		IN THE HOUSE OF REPRESENTATIVES

			May 26, 2011
			Mr. Grijalva
			 submitted the following resolution; which was referred to the
			 Committee on Natural
			 Resources

		RESOLUTION
		Honoring wild horses and burros as
		  important to our national heritage.

		Whereas the evolutionary origin of equines is found in
			 North America;
		Whereas wild horses and burros are part of the ecosystem
			 and rangelands of the United States;
		Whereas wild horses and burros are an important part of
			 our national heritage;
		Whereas the National Wild Horse and Burro Program should
			 provide for continued long-term existence and well-being of wild horses and
			 burros on public lands; and
		Whereas Cloud, the most famous and revered wild stallion,
			 was born May 29, 1995, on the Pryor Mountain Wild Horse Range, and embodies the
			 essence of wild horse values of freedom and family: Now, therefore, be
			 it

		That the House of Representatives—
			(1)honors the 16th
			 birthday of Cloud;
			(2)encourages the
			 people of the United States to observe and celebrate the 16th birthday of Cloud
			 and the intrinsic value of all wild horses and burros;
			(3)recognizes wild
			 horses and burros as living symbols of the western development era and honors
			 their hardy nature; and
			(4)recognizes that
			 with the American frontier long since closed, wild horses and burros remain
			 among the last representatives of the freedom and spirit of the Old
			 West.


117 HR 4809 IH: Patient Access to ESRD New Innovative Devices Act
U.S. House of Representatives
2021-07-29
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS1st SessionH. R. 4809IN THE HOUSE OF REPRESENTATIVESJuly 29, 2021Mr. Danny K. Davis of Illinois introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend title XVIII of the Social Security Act to improve access to innovative new medical devices furnished to individuals with end stage renal disease under part B of the Medicare program by establishing a new device add-on payment adjustment under such part.1.Short titleThis Act may be cited as the Patient Access to ESRD New Innovative Devices Act.2.FindingsCongress finds the following:(1)There are approximately 400,000 Medicare beneficiaries with end-stage renal disease, making up 1 percent of the Medicare population but accounting for approximately 7 percent of all Medicare spending.(2)Expected remaining lifetime for dialysis patients under 80 years old is one-third as long as their counterparts without ESRD, and for dialysis patients over 80 years old, it is one-half as long as that of their counterparts without ESRD.(3)On average, hemodialysis patients are hospitalized nearly twice per year and about 30 percent have an unplanned rehospitalization within the 30 days following discharge, contributing to high costs for treating ESRD Medicare beneficiaries.(4)There is a lack of innovative new devices for ESRD Medicare beneficiaries, in part because of the lack of reimbursement incentives for novel devices.3.Temporary add-on payment for new medical devices to diagnose, treat, or manage end stage renal diseaseThe Secretary of Health and Human Services shall provide—(1)a three-year temporary add-on payment adjustment (as described in section 413.236(d) of title 42, Code of Federal Regulations) for a new medical device approved by the Food and Drug Administration under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c) on or after January 1, 2020, and furnished to an individual entitled to benefits under part B of title XVIII of the Social Security Act for the diagnosis, treatment, or management of end stage renal disease; and(2)for the adjustment under paragraph (1) to be implemented in a nonbudget neutral manner under subparagraph (D)(iv) of section 1881(b)(14) of the Social Security Act (42 U.S.C. 1395rr(b)(14)(D)(iv)).


115 HR 3410 IH: Stop Infant Mortality And Recidivism Reduction Act of 2017
U.S. House of Representatives
2017-07-26
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 3410IN THE HOUSE OF REPRESENTATIVESJuly 26, 2017Ms. Jackson Lee (for herself, Mr. Conyers, Mr. Cicilline, Ms. Moore, Mrs. Napolitano, Mr. Hastings, Ms. Wilson of Florida, Mr. McNerney, Mr. Danny K. Davis of Illinois, Mr. Rush, Ms. Plaskett, Mr. Cohen, Ms. DeLauro, Mr. Johnson of Georgia, Mr. McGovern, Ms. Bass, Ms. Sewell of Alabama, Mr. Al Green of Texas, and Mr. Richmond) introduced the following bill; which was referred to the Committee on the JudiciaryA BILLTo enhance public health and safety by improving the effectiveness and efficiency of the Federal
			 prison system for incarcerated pregnant women and mothers by establishing
			 a pilot program of critical-stage, developmental nurseries in Federal
			 prisons for children born to inmates, with risk and needs assessments, and
			 risk and recidivism reduction.

 1.Short titleThis Act may be cited as the Stop Infant Mortality And Recidivism Reduction Act of 2017 or the SIMARRA Act. 2.Establishment Not later than 270 days after the date of the enactment of this Act, the Director of the Federal Bureau of Prisons (hereinafter referred to as the Director) shall establish a pilot program (hereinafter referred to as the Program) in accordance with this Act to permit women incarcerated in Federal prisons and the children born to such women during incarceration to reside together while the inmate serves a term of imprisonment in a separate housing wing of the prison.
 3.PurposesThe purposes of the Act are to— (1)prevent infant mortality among infants born to incarcerated mothers and greatly reduce the trauma and stress experienced by the unborn fetuses of pregnant inmates;
 (2)reduce the recidivism rates of federally incarcerated women and mothers, and enhance public safety by improving the effectiveness of the Federal prison system for women as a population with special needs;
 (3)establish female offender risk and needs assessment as the cornerstones of a more effective and efficient Federal prison system;
 (4)implement a validated post-sentencing risk and needs assessment system that relies on dynamic risk factors to provide Federal prison officials with a roadmap to address the pre- and post-natal needs of Federal pregnant offenders, manage limited resources, and enhance public safety;
 (5)perform regular outcome evaluations of the effectiveness of programs and interventions for federally incarcerated pregnant women and mothers to assure that such programs and interventions are evidence-based and to suggest changes, deletions, and expansions based on the results of such evaluations; and
 (6)assist the Department of Justice to address the underlying cost structure of the Federal prison system and ensure that the Department can continue to run prison nurseries safely and securely without compromising the scope or quality of the Department’s critical health, safety and law enforcement missions.
			4.Duties of the Director of Federal Bureau of Prisons
 (a)In generalThe Director shall carry out this section in consultation with— (1)a licensed and board-certified gynecologist or obstetrician;
 (2)the Director of the Administrative Office of the United States Courts; (3)the Director of the Office of Probation and Pretrial Services;
 (4)the Director of the National Institute of Justice; and (5)the Director of the U.S. Department of Health & Human Services.
 (b)DutiesThe Director shall, in accordance with subsection (c)— (1)develop an offender risk and needs assessment system particular to the health and sensitivities of federally incarcerated pregnant women and mothers in accordance with this section;
 (2)develop recommendations regarding recidivism reduction programs and productive activities in accordance with section 9;
 (3)conduct ongoing research and data analysis on— (A)the best practices relating to the use of offender risk and needs assessment tools particular to the health and sensitivities of federally incarcerated pregnant women and mothers;
 (B)the best available risk and needs assessment tools particular to the health and sensitivities of federally incarcerated pregnant women and mothers and the level to which they rely on dynamic risk factors that could be addressed and changed over time, and on measures of risk of recidivism, individual needs, and responsivity to recidivism reduction programs;
 (C)the most effective and efficient uses of such tools in conjunction with recidivism reduction programs, productive activities, incentives, and rewards; and
 (D)which recidivism reduction programs are the most effective— (i)for federally incarcerated pregnant women and mothers classified at different recidivism risk levels; and
 (ii)for addressing the specific needs of federally incarcerated pregnant women and mothers; (4)on a biennial basis, review the system developed under paragraph (1) and the recommendations developed under paragraph (2), using the research conducted under paragraph (3), to determine whether any revisions or updates should be made, and if so, make such revisions or updates;
 (5)hold periodic meetings with the individuals listed in subsection (a) at intervals to be determined by the Director; and
 (6)report to Congress in accordance with section 9. (c)MethodsIn carrying out the duties under subsection (b), the Director shall—
 (1)consult relevant stakeholders; and (2)make decisions using data that is based on the best available statistical and empirical evidence.
 5.EligibilityAn inmate may apply to participate in the Program if the inmate— (1)is pregnant at the beginning of the term of imprisonment; and
 (2)is in the custody or control of the Federal Bureau of Prisons. 6.Program terms (a)Term of participationTo correspond with the purposes and goals of the program to promote bonding during the critical stages of child development, an eligible inmate selected for the Program may participate in the Program, subject to section 7, for the shorter of the inmate’s term of imprisonment or 30 months.
 (b)Inmate requirementsFor the duration of an inmate’s participation in the Program, the inmate shall agree to— (1)accept the responsibility of child-rearing;
 (2)participate in any educational or counseling opportunities established by the Director, including topics such as child development, parenting skills, domestic violence, vocational training, or substance abuse;
 (3)abide by any court decision regarding the legal or physical custody of the child; (4)transfer to the Federal Bureau of Prisons any child support payments for the infant of the participating inmate from any person or governmental entity; and
 (5)specify a person who has agreed to take custody of the child if the inmate’s participation in the Program terminates before the inmate’s release.
 7.Termination of participationAn inmate’s participation in the Program terminates upon the earliest of the following to occur: (1)The inmate is released from prison.
 (2)The infant fails to meet any medical criteria established by the Director or the Director’s designee along with a collective determination of the persons listed in section 4(a).
			8.Continuity of care
 The Director shall take appropriate actions to prevent detachment or disruption of either an inmate’s or infant’s health and bonding-based well-being due to termination of the Program.
		9.Reporting
 (a)In generalNot later than 6 months after the date of the enactment of this Act and once every year thereafter for 5 years, the Director shall submit a report to the Congress with regards to progress in implementing the Program.
 (b)Final reportNot later than 6 months after the termination of the Program, the Director shall issue a final report to the Congress that contains a detailed statement of the Director’s findings and conclusions, including recommendations for legislation, administrative actions, and regulations the Director considers appropriate.
 10.Authorization of appropriationsTo carry out this Act, there is authorized to be appropriated $10,000,000 for each of fiscal years 2017 through 2021.